New Application Notes Published

In Q1-2026, we generated several application notes to illustrate how our products can be of use for EV researchers. You can follow the links before to learn more!

Platelet EVs: A New Reference Material from Blood Components with Superior Purity over Plasma EVs: In collaboration with SPARTA Biodiscovery, this application note demonstrates the superior purity of platelet EVs in comparison to their plasma counterparts, proving them useful in theranostics or cosmeceutical settings.

Going Beyond Eukaryotes: Purification of Bacterial EVs: Bacterial EVs are attracting research interest for their potential use in drug delivery, therapeutics, or even cosmetics applications. This application note illustrates how TFF-based bacteria EV isolation can respond to the need for large-scale manufacturing.

Beyond First Impression: The Reusability of TFF Cartridges: TFF cartridges are reusable multiple times, but how? In order to respond to this frequently-received question, we demonstrated how the main performance criteria of EV isolation vary across repetitive cycles of use of TFF with HEK293 and MSC culture medium.

Working with Primary Cancers: TFF+SEC for High-Efficiency EV Isolation: Even though immortalized cancer cell lines are much more common in EV research, primary cancer cell lines are able to provide deeper insight into cancer progression with higher biological relevance. This study demonstrates how our optimized EV isolation protocol works also on primary cancer cell line EVs, which are now offered as custom-made EV standards by HansaBioMed.